Evoke Pharma Reports Positive Growth in Q2 Financials

Author: Evelyn Baker Updated: 08-14-2025 07:13 AM

Evoke Pharma Shows Strong Financial Results for Q2 2025

Evoke Pharma, Inc. (NASDAQ: EVOK), a pharmaceutical company specializing in treatments for gastrointestinal disorders, has recently released its financial results for the second quarter. With a focus on its product GIMOTI, the company is celebrating significant achievements in sales growth and market adoption.

Quarter Highlights and Developments

During this quarter, Evoke Pharma demonstrated impressive growth with net product sales reaching approximately $3.8 million, marking a 47% increase compared to the same period last year. This growth is attributed to enhanced pharmacy access and increasing physician prescriptions.

Key Metrics of Growth

The number of new prescribers rose 20% year-over-year, showcasing a positive trend within the gastroenterology sector.
Refill rates remained stable at around 70%, indicating consistent therapeutic benefits of GIMOTI for patients.
Real-world safety data presented at a major digestive disease conference highlighted GIMOTI’s efficacy compared to traditional metoclopramide usage.

Financial Overview for Q2 2025

In reviewing the financials for the quarter, total operating expenses increased to approximately $5.3 million compared to $3.8 million in Q2 2024. Major contributors included increased profit-sharing costs due to the uptick in net product sales and heightened professional fees.

Cash Position and Future Outlook

As of June 30, 2025, Evoke’s cash and cash equivalents totaled approximately $12.1 million, projected to support its operational needs until the third quarter of 2026 based on current sales trends.

Guidance for 2025

Evoke Pharma is reaffirming its guidance for full-year 2025 net product sales, predicting approximately $16 million—an expected increase of 60% over last year. This outlook considers the current trends in prescription growth, refill rates, and overall market demand for GIMOTI.

About Evoke Pharma, Inc.

Founded to develop innovative therapies for gastrointestinal disorders, Evoke has successfully brought GIMOTI to market. This nasal spray formulation of metoclopramide offers a vital alternative to patients suffering from diabetic gastroparesis, a condition that affects many worldwide.

What is Diabetic Gastroparesis?

Diabetic gastroparesis is a serious disorder where the stomach takes too long to empty its contents, leading to various complications, including poor nutrient absorption. Prior to the approval of GIMOTI, metoclopramide was available only in oral and injectable forms.

Investor Contact Information

For further inquiries, please contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
Email: dboateng@dkbpartners.net

Frequently Asked Questions

What trends contributed to Evoke Pharma's growth this quarter?

The growth has been fueled by a 47% annual increase in net product sales and a growing number of new prescribers, reflecting strong demand for GIMOTI.

How is Evoke Pharma's financial outlook for 2025?

For 2025, Evoke Pharma anticipates net product sales of about $16 million, projecting a significant increase compared to the previous year.

What is GIMOTI and its importance?

GIMOTI is a nasal spray designed for patients with diabetic gastroparesis, offering a crucial treatment option that enhances medication absorption compared to traditional forms.

How does Evoke Pharma plan to sustain its growth?

The company aims to continue expanding pharmacy access and increasing physician adoption to bolster its market presence and sales.

What are the risks associated with GIMOTI?

While GIMOTI is effective, potential risks include adverse side effects commonly associated with metoclopramide, such as tardive dyskinesia.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.